SLC29A1在泛癌中的表达及其临床意义  

The expression and clinical significance of SLC29A1 in pan-cancer

作　　者：寇茜睿 沈慧 邵琳鑫 张静[1,2] 李芳 KOU Qianrui;SHEN Hui;SHAO Linxin;ZHANG Jing;LI Fang(Medical College of Yan′an University,Yan′an 716000,China;Medical Research and Experimental Center of the Second Affiliated Hospital of Xi′an Medical University,Xi′an 710299,China)

机构地区：[1]延安大学医学院,陕西延安716000 [2]西安医科大学第二附属医院医学研究试验中心,陕西西安710299

出　　处：《延安大学学报（医学科学版）》2024年第3期36-44,共9页Journal of Yan'an University:Medical Science Edition

摘　　要：目的 分析溶质载体家族1号基因(solute carrier family 29 member 1, SLC29A1, ENT1)在泛癌中的表达及其临床意义。方法 利用数据库分析SLC29A1在泛癌中的表达水平及其与肿瘤患者生存期、免疫浸润、免疫检查点、肿瘤突变负荷、微卫星不稳定性、趋化因子及趋化因子受体的关系,并分析SLC29A1在泛癌中的突变特征及SLC29A1与泛癌生物学行为的关系。结果 SLC29A1在急性成淋巴细胞性白血病(acute lymphoblastic leukemia,ALL)、胶质母细胞瘤(glioblastoma,GMBLGG)、脑低级别胶质瘤(lower-grade glioma, LGG)等13种肿瘤中呈显著高表达;而在子宫内膜癌(uterine corpus endometrial carcinoma, UCEC)、宫颈鳞癌和腺癌(cervical squamous cell carcinoma and endocervical adenocarcinoma, CESC)、肺鳞癌(lung squamous cell carcinoma, LUSC)等18种肿瘤中呈显著低表达。且SLC29A1表达水平与肾上腺皮质癌(adrenocortical carcinoma, ACC)患者预后呈正相关,而与LGG患者预后呈负相关。SLC29A1在前列腺癌(prostate adenocarcinoma, PRAD)中的表达水平越高,免疫细胞浸润程度越高,基质评分、免疫评分和基质免疫评分越高。SLC29A1在PRAD中与大多数免疫检查点相关基因呈正相关,而在胸腺癌(thymoma, THYM)中与ENTPD1、TLR4等免疫激活因子呈负相关。SLC29A1在间皮瘤(mesothelioma,MESO)中与趋化因子CX3CL1呈显著正相关,而在多形性胶质母细胞瘤(glioblastoma multiforme,GBM)中与趋化因子受体CXCR2呈显著正相关。SLC29A1在GBMLGG、LGG中与肿瘤突变负荷显著正相关,而在胃腺癌(stomach adenocarcinoma, STAD)中与肿瘤突变负荷和微卫星不稳定性显著负相关。SLC29A1在食管腺癌患者突变频率最高,且在大多数肿瘤中SLC29A1均与DNA损伤呈正相关。结论 SLC29A1与多种肿瘤的预后、免疫浸润、免疫检查点、肿瘤突变负荷、微卫星不稳定性及肿瘤生物学行为等密切相关,提示其可能成为富有前景的肿瘤治疗靶点。Objective To determine the expression and clinical significance of solute carrier family 29 member 1(SLC29A1,also known as ENT1)in pan-cancer.Methods With the help of databases,the expression level of SLC29A1 in pan-cancer was analyzed,and its relationship with survival time,immune infiltration,immune checkpoint,tumor mutational burden,microsatellite instability,chemokines and chemokine receptors,as well as the mutation characteristics of SLC29A1 in pan-cancer and the relationship between SLC29A1 and the functional status of pancancer were analyzed.Results SLC29A1 was significantly highly expressed in 13 tumors including acute lymphoblastic leukemia(ALL),glioblastoma(GMBLGG),lower-grade glioma(LGG);while markedly lowly expressed in 18 tumors including uterine corpus endometrial carcinoma(UCEC),cervical squamous cell carcinoma and endocervical adenocarcinoma( CESC), lung squamous cell carcinoma(LUSC). The expression level of SLC29A1was positively associated with the prognosis of adrenocortical carcinoma (ACC), and negatively associated with theprognosis of LGG. The higher the expression level of SLC29A1 in prostate adenocarcinoma (PRAD), the higherthe abundance of immune cell infiltration, and the higher the matrix score, immune score, and matrix immunescore. SLC29A1 was positively associated with most immune checkpoint-related genes in PRAD, but negativelyassociated with immune stimulators such as ENTPD1 and TLR4 in thymoma(THYM). SLC29A1 was significantlypositively correlated with chemokine CX3CL1 in mesothelioma(MESO) and chemokine receptor CXCR2 inglioblastoma multiforme (GBM). SLC29A1 was positively correlated with tumor mutational burden in GBMLGGand LGG, and negatively correlated with tumor mutational burden and microsatellite instability in stomachadenocarcinoma (STAD). SLC29A1 demonstrated the highest mutation rate in esophageal adenocarcinoma, andthere was a positive correlation between SLC29A1 and DNA damage across most tumors. Conclusion SLC29A1 isclosely related to the prognosis, immune infiltration,

关 键 词：SLC29A1 泛癌 表达水平 

分 类 号：R735.9[医药卫生—肿瘤]